Merck & Co Inc (NYSE: MRK) has reported earnings for its fourth fiscal quarter (ending December 31) of $1.48 versus a loss $-0.48 for the same period a year ago — a decline of -408%. For the latest four quarters through December 31, E.P.S. were $6.74 versus $0.14 for the same period a year ago — an increase of 4714%.
Recent Price Action
Merck & Co Inc (NYSE: MRK) stock closed at $90.74 on 2/4/25 after a large decline of -9.1%. Moreover, trading volume in this decline was exceptionally high at 419% of normal. The stock has been weak relative to the market over the last nine months and has declined -7.4% during the last week.
Current PriceTarget Research Rating
Merck has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Merck has a good Appreciation Score of 72 but a very low Power Rating of 13, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment